Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, reviews recent progress and provides an outlook for 2018:
“In 2017, our newly-assembled team achieved our stated goal of transforming Adverum into a clinical-stage company,” said Amber Salzman, Ph.D., president and CEO of Adverum Biotechnologies. “We are accelerating the development of our pipeline of gene therapies and plan to submit an investigational new drug application with the FDA in the second half of 2018, for ADVM-053 in HAE. With our platform of industry-leading technology and experienced leadership team, we are well positioned to advance our pipeline of novel gene therapies in 2018.”
(Source: Adverum)
